Back to results
US 2023/0323468 A1Published application
Immune gene signatures in muscle invasive bladder cancer
AssigneeH. Lee Moffitt Cancer Center and Research Institute, Inc.
InventorsRoger Li, James J. Mulé, Anders Erik Berglund
Life of this patent
Estimating the term…
Abstract
This invention relates to methods for selecting a treatment and optionally treating subjects with muscle-invasive bladder cancer based on tumor expression levels of chemokines, cytotoxic genes, and/or dendritic cell genes.
Claims8
A method of treating a subject who has muscle-invasive bladder cancer (MIBC), the method comprising:
- obtaining cells from the tumor;
- determining expression levels of CCL2, CCL3, CCL4, CCL5, CCL8, CCL18, CCL19, CCL21, CXCL9, CXCL10, CXCL11, and CXCL13 in the tumor cells;
- comparing the tumor gene expression levels to reference gene expression levels;
- selecting for the subject a first line treatment comprising surgical resection and immunotherapy and/or adjuvant chemotherapy if tumor gene expression levels are above the reference gene expression levels.
1 more element
Dependencies are inferred from the claim text.